Investigator's Brochure (IB) Table
Drugs
| Drug Name | Drug Company | IB Date Sort descending | Risk List Available? |
|---|---|---|---|
| Vorinostat (Zolinza) | Merck | August 2013 | |
| Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Remdesivir (Veklury) | Gilead Sciences | June 2021 | |
| Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) | Merck | July 2021 | |
| TBI-223 | Global Alliance for TB Drug Development (TB Alliance) | October 2023 | |
| Pretomanid (PA-824) | Global Alliance for TB Drug Development (TB Alliance) | November 2023 | |
| Glecaprevir/Pibrentasvir - New - New | AbbVie | January 2024 | |
| Dapivirine (Vaginal Ring) | International Partnership For Microbicides | May 2024 | |
| Rilpivirine (TMC278, Edurant) | Janssen Research & Development | July 2024 | |
| Delamanid (OPC-67683) | Otsuka | August 2024 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | October 2024 | |
| Bedaquiline (TMC207) | Janssen Research & Development | October 2024 | |
| Tenofovir | Conrad | November 2024 | |
| Tecovirimat (TPOXX) | SIGA Technologies, Inc. | January 2025 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | January 2025 | |
| Quercefit (Quercetin Phospholipid) - New - New | Indena | February 2025 | |
| Sutezolid - New - New | Global Alliance for TB Drug Development (TB Alliance) | April 2025 |
Vaccines
| Vaccine Name | Vaccine Company | IB Date Sort descending | Risk List Available? |
|---|---|---|---|
| p24CE1/2 multivalent pDNA Vaccine expressing HIV M Group p24 Gag and p55 gag pDNA with IL-12 pDNA | NCI/NIAID/NIH | November 2017 | |
| RSV 276 | LID/NIAID/NIH | February 2019 | |
| RSV DeltaNS2-Delta1313-I1314L | LID/NIAID/NIH | February 2019 | |
| RSV 6120/DeltaNS2/1030s | LID/NIAID/NIH | March 2019 | |
| VRC-HIVMAB060-00-AB (VRC01) | VRC/NIAID | August 2019 | |
| MVA-CMDR | Walter Reed Army Institute Research (WRAIR) | November 2019 | |
| PGT121 | Beth Israel Deaconess Medical Center | September 2020 | |
| PGDM1400 | Beth Israel Deaconess Medical Center | March 2021 | |
| AdC6-HIVgp140, AdC7-HIVgp140, CH505TF/GLA-SE Vaccines | DAIDS/NIAID/NIH | March 2021 | |
| HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL) | VRC/NIAID/NIH | July 2021 | |
| EnvSeq-1 and EnvSeq-2 | DAIDS/NIAID/NIH | October 2022 | |
| Selgantolimod (GS-9688) | Gilead | January 2023 | |
| GLA-SE | Infectious Disease Research Institute (IDRI) | May 2023 | |
| PGT121.414.LS (VRC-HIVMAB0107-00-AB) | VCMP/NIAID/NIH | June 2023 | |
| VRC-HIVRGP096-00-VP (HIV-1 Trimer 4571 Vaccine) | VRC/NIAID/NIH | August 2023 | |
| 3M-052-AF | Access to Advanced Health Institute (AAHI) | November 2023 | |
| 16055 NFL Delta Gly4 Env Protein Trimer, Adjuvanted with 3M-052 AF + Alum | DAIDS/NIAID/NIH | December 2023 | |
| N-803 | Altor BioScience (ImmunityBio) | December 2023 | |
| Poly-ICLC (Hiltonol) | Oncovir, Inc. | January 2024 | |
| BG505 SOSIP.GT1.1 gp140 Vaccine | International AIDS Vaccine Initiative (IAVI) | January 2024 |